BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27487259)

  • 21. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.
    Yatham LN; Fallu A; Binder CE
    Acta Psychiatr Scand Suppl; 2007; (434):50-6. PubMed ID: 17688463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
    McIntyre RS
    Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and tolerability of atypical antipsychotics in bipolar disorder.
    Seemüller F; Forsthoff A; Dittmann S; Born C; Bernhard B; Severus WE; Grunze H
    Expert Opin Drug Saf; 2005 Sep; 4(5):849-68. PubMed ID: 16111448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia.
    Kemp DE; Gilmer WS; Fleck J; Straus JL; Dago PL; Karaffa M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):574-7. PubMed ID: 17234318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials.
    Li DJ; Tseng PT; Stubbs B; Chu CS; Chang HY; Vieta E; Fornaro M; Carvalho AF; Solmi M; Veronese N; Chen TY; Chen YW; Lin PY; Chow PC
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):289-301. PubMed ID: 28651936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug safety evaluation of aripiprazole in bipolar disorder.
    Cuomo A; Beccarini Crescenzi B; Goracci A; Bolognesi S; Giordano N; Rossi R; Facchi E; Neal SM; Fagiolini A
    Expert Opin Drug Saf; 2019 Jun; 18(6):455-463. PubMed ID: 31072228
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
    Perlis RH
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.
    Tramontina S; Zeni CP; Ketzer CR; Pheula GF; Narvaez J; Rohde LA
    J Clin Psychiatry; 2009 Apr; 70(5):756-64. PubMed ID: 19389329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
    Aladeen T; Westphal E; Lee Y; Rong C; Rainka M; Capote H; McIntyre RS
    Perspect Psychiatr Care; 2018 Oct; 54(4):507-513. PubMed ID: 29427512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.
    Vieta E; T'joen C; McQuade RD; Carson WH; Marcus RN; Sanchez R; Owen R; Nameche L
    Am J Psychiatry; 2008 Oct; 165(10):1316-25. PubMed ID: 18381903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
    Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
    J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
    Findling RL; Correll CU; Nyilas M; Forbes RA; McQuade RD; Jin N; Ivanova S; Mankoski R; Carson WH; Carlson GA
    Bipolar Disord; 2013 Mar; 15(2):138-49. PubMed ID: 23437959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
    Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
    Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
    Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
    Schizophr Res; 2016 Jul; 174(1-3):120-125. PubMed ID: 27157800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotic tolerability and switching strategies in bipolar disorder.
    Liauw SS; McIntyre RS
    Expert Opin Pharmacother; 2010 Dec; 11(17):2827-37. PubMed ID: 20726821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients.
    Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
    Psychiatry Res; 2009 Jan; 165(1-2):193-6. PubMed ID: 18973955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.